exRNAdisease

Entry Detail

---



General Information

Database ID: exR0371332 RNA Name: TOB2 RNA Type: mRNA Chromosome: chr22 Starnd: - Coordinate: Start Site(bp): 41433494 End Site(bp): 41446801 External Links: ENSG00000183864

Disease Information

Disease Name: Amyotrophic Lateral Sclerosis Disease Category: Nervous System Diseases MeSH ID: D000690 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Amyotrophic Lateral//Gehrig's Disease//Gehrig Disease//Gehrigs Disease//Charcot Disease//Motor Neuron Disease, Amyotrophic Lateral Sclerosis//Lou Gehrig's Disease//Lou-Gehrigs Disease//Disease, Lou-Gehrigs//ALS - Amyotrophic Lateral Sclerosis//ALS Amyotrophic Lateral Sclerosis//Lou Gehrig Disease//Amyotrophic Lateral Sclerosis, Guam Form//Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1//Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1//Guam Form of Amyotrophic Lateral Sclerosis//Guam Disease//Disease, Guam//Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam//Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam//Amyotrophic Lateral Sclerosis With Dementia//Dementia With Amyotrophic Lateral Sclerosis

Expression Detail

GEO ID: GSE121519 Description: Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. Experimental Design: Disease vs Control Case Disease Type: Amyotrophic Lateral Sclerosis Case Disease SubType: NA Case Sample: Amyotrophic Lateral Sclerosis Control Sample: Healthy Number of Case: 4 Number of Control: 4 Number of Samples: 8

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABL1 chr9 130713016 130887675 + AC004922.1 chr7 99325879 99394653 + AC008878.3 chr19 7382834 7470241 + ACBD6 chr1 180269653 180502954 - ADGRA3 chr4 22345071 22516066 - AHCY chr20 34280268 34311802 - AKAP1 chr17 57085092 57121346 + AL136295.4 chr14 24180395 24190416 - miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-miR-16-5p chr3 160404754 160404775 + hsa-miR-23a-3p chr19 13836595 13836615 - hsa-miR-103a-3p chr5 168560904 168560926 - hsa-miR-107 chr10 89592756 89592778 - hsa-miR-34a-5p chr1 9151735 9151756 - hsa-miR-23b-3p chr9 95085265 95085287 + hsa-miR-135a-5p chr12 97563834 97563856 + hsa-miR-195-5p chr17 7017667 7017687 - hsa-miR-34c-5p chr11 111513451 111513473 + hsa-miR-378a-3p chr5 149732867 149732888 + hsa-miR-135b-5p chr1 205448361 205448383 - hsa-miR-422a chr15 63870989 63871010 - hsa-miR-424-5p chrX 134546680 134546701 - hsa-miR-432-5p chr14 100884496 100884518 + hsa-miR-512-3p chr19 53666729 53666750 + hsa-miR-520a-5p chr19 53690895 53690915 + hsa-miR-545-3p chrX 74287126 74287147 - hsa-miR-654-5p chr14 101040234 101040255 + hsa-miR-708-5p chr11 79402077 79402099 - circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC064802.1 chr8 114282067 114295839 + AD000090.1 chr19 35557956 35581954 + AL117378.1 chr6 131901963 131920565 + Display:

Experiment Detail

GEO ID: GSE121519 Sample Source: Cerebrospinal Fluid Source Fraction: Exosome Platform: GPL18573 Method: NGS Num of detected RNA Type: 2 Num of detected RNAs of this Type: 17787 Sample treatment protocol: Up to 1 mL of human CSF was centrifuged at 2,000×g for 5 min and 10, 000×g for 20 min for supernatant. RNA Extract protocol: Supernatant from final centrifugation was applied to exoRNeasy spin column and RNA was extracted. RNA library preparation protocol: Whole cDNA amplification was performed with SMART-seq v4 Ultra Low Input RNA Kit. Illumina library was constructed with Nextera XT DNA Library Prep Kit.

Reference

PMID: 30630471 Title: Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid Author: Otake K, Kamiguchi H, Hirozane Y Journal: BMC Med Genomics. 2019 Jan 10;12(1):7. Description: The main purpose of this study is to established the methodology of comprehensive analysis of exosomal mRNAs in CSF by a highly sensitive next-generation sequencing.